-
Cardiac Drug ReoPro: Clinical Trial Is Suspended by Lilly and J&J
Drug Companies Had Been Testing ReoPro for Treatment of Ischemic Strokes On October 5, 2005 it was reported that Eli Lilly & Co. ("Lilly") and Johnson & Johnson ("J&J") have temporarily suspended a late-stage…
-
FDA to Search for Emerging Drug-safety Issues in Health Insurance Company Databases
Public Meeting About Communicating Drug Risks to be Convened in December 2005 In early October 2005 the FDA announced that it has contracted with several large health insurance companies to gain access to their…
-
Bextra: Strong Association With Stevens-Johnson Syndrome (“SJS”) and Toxic Epidermal Necrolysis (“TEN”)
SJS and TEN are Severe Acute Life-threatening, Drug-induced Skin Disorders Linked to Bextra and Celebrex Stevens-Johnson syndrome and toxic epidermal necrolysis are closely related severe acute life-threatening, drug-induced skin disorders. The FDA Adverse Events…
-
The Chance of Having an Adverse Drug Reaction Event Increases With Patient Age
Drug-drug Interactions are a Leading Cause of Drug Reactions, and Growing Due to Polypharmacy Because older adults often take more medications than younger adults, the number of adverse drug reactions increases with patient age.…
-
Merck’s Kenneth Frazier and Congressman Waxman Differ Over “The Lessons of Vioxx”
Merck’s General Counsel Frazier Takes Issue With Congressman Henry Waxman’s June 2005 NEJM Article In the September 29, 2005 edition of The New England Journal of Medicine ("NEJM") is a letter to the editor…
-
Paxil Label to Get an Increased Warning About Possible Birth Defects
Glaxo Says It Does Not Know Whether Paxil Causes Any Abnormality or Malformation in Babies A September 27, 2005 FDA MedWatch alert broadcast the news that GlaxoSmithKline Plc had sent a "Dear Doctor" letter…
